Neovii and VINS exchange NDA to explore immunoglobulin collaboration

The Economic Times reports, citing India’s embassy in Berlin, that Germany’s Neovii Biotech and India’s VINS Bioproducts exchanged a non-disclosure agreement on October 13, 2026. The agreement is intended to facilitate manufacturing, technology transfer to India and commercialisation of immunoglobulin products, including anti-thymocyte globulin, which is used in organ transplants and to treat certain blood disorders.